Form 4: United Therapeutics Director Louis W. Sullivan Executes Stock Options and Sells Shares

Sentiment:

SEC Form 4 Filing


Director Louis W. Sullivan exercised stock options and sold shares of United Therapeutics Corp on May 3, 2024.

Summary

  • On May 3, 2024, Louis W. Sullivan, a director of United Therapeutics Corporation, exercised stock options to acquire 5,160 shares of common stock at a price of $119.76 per share.
  • Sullivan then sold 2,181 shares at a weighted average price of $257.3895, with individual trades ranging from $256.98 to $257.51.
  • He also sold 2,979 shares at a weighted average price of $259.1199, with individual trades ranging from $258.49 to $259.395.
  • Following these transactions, Sullivan directly owns 13,060 shares of United Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating neutral sentiment. It simply reports transactions by a company insider.

Industry Context

This filing reflects insider trading activity, which is a common occurrence in publicly traded companies. Investors often monitor these filings to gain insights into management's perspective on the company's stock and future prospects.

Stakeholder Impact

  • Shareholders may interpret the insider's sale of shares as a signal, although it could be for personal financial reasons.

Key Dates

DateDescription
06/26/2021Date exercisable for stock options
05/03/2024Date of stock option exercise and share sales
05/06/2024Date of signature on the Form 4 filing
06/26/2030Expiration date for stock options

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.